191 related articles for article (PubMed ID: 21572364)
1. PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma.
Sadri K; Ren Q; Zhang K; Paudyal B; Devadhas D; Rodeck U; Thakur M
Nucl Med Commun; 2011 Jul; 32(7):563-9. PubMed ID: 21572364
[TBL] [Abstract][Full Text] [Related]
2. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.
Ping Li W; Meyer LA; Capretto DA; Sherman CD; Anderson CJ
Cancer Biother Radiopharm; 2008 Apr; 23(2):158-71. PubMed ID: 18454685
[TBL] [Abstract][Full Text] [Related]
3. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.
Reilly RM; Kiarash R; Sandhu J; Lee YW; Cameron RG; Hendler A; Vallis K; Gariépy J
J Nucl Med; 2000 May; 41(5):903-11. PubMed ID: 10809207
[TBL] [Abstract][Full Text] [Related]
4.
Kwon LY; Scollard DA; Reilly RM
Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
[TBL] [Abstract][Full Text] [Related]
5. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225.
Wen X; Wu QP; Ke S; Ellis L; Charnsangavej C; Delpassand AS; Wallace S; Li C
J Nucl Med; 2001 Oct; 42(10):1530-7. PubMed ID: 11585869
[TBL] [Abstract][Full Text] [Related]
6. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
[TBL] [Abstract][Full Text] [Related]
7. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.
Aerts HJ; Dubois L; Perk L; Vermaelen P; van Dongen GA; Wouters BG; Lambin P
J Nucl Med; 2009 Jan; 50(1):123-31. PubMed ID: 19091906
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.
McLarty K; Fasih A; Scollard DA; Done SJ; Vines DC; Green DE; Costantini DL; Reilly RM
J Nucl Med; 2009 Nov; 50(11):1848-56. PubMed ID: 19837760
[TBL] [Abstract][Full Text] [Related]
9. A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice.
Panosa C; Fonge H; Ferrer-Batallé M; Menéndez JA; Massaguer A; De Llorens R; Reilly RM
Nucl Med Biol; 2015 Dec; 42(12):931-8. PubMed ID: 26385534
[TBL] [Abstract][Full Text] [Related]
10. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts.
Ke S; Wen X; Gurfinkel M; Charnsangavej C; Wallace S; Sevick-Muraca EM; Li C
Cancer Res; 2003 Nov; 63(22):7870-5. PubMed ID: 14633715
[TBL] [Abstract][Full Text] [Related]
11. 99mTc-Hydrazinonicotinamide epidermal growth factor-polyethylene glycol-quantum dot imaging allows quantification of breast cancer epidermal growth factor receptor expression and monitors receptor downregulation in response to cetuximab therapy.
Jung KH; Choe YS; Paik JY; Lee KH
J Nucl Med; 2011 Sep; 52(9):1457-64. PubMed ID: 21849406
[TBL] [Abstract][Full Text] [Related]
12. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody.
Cai W; Chen K; He L; Cao Q; Koong A; Chen X
Eur J Nucl Med Mol Imaging; 2007 Jun; 34(6):850-8. PubMed ID: 17262214
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3.
Cai W; Wu Y; Chen K; Cao Q; Tice DA; Chen X
Cancer Res; 2006 Oct; 66(19):9673-81. PubMed ID: 17018625
[TBL] [Abstract][Full Text] [Related]
15. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.
Nayak TK; Regino CA; Wong KJ; Milenic DE; Garmestani K; Baidoo KE; Szajek LP; Brechbiel MW
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1368-76. PubMed ID: 20155263
[TBL] [Abstract][Full Text] [Related]
16. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
[TBL] [Abstract][Full Text] [Related]
17. PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies.
Liu S; Li D; Park R; Liu R; Xia Z; Guo J; Krasnoperov V; Gill PS; Li Z; Shan H; Conti PS
J Nucl Med; 2013 Jul; 54(7):1094-100. PubMed ID: 23667241
[TBL] [Abstract][Full Text] [Related]
18. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
[TBL] [Abstract][Full Text] [Related]
19. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
20. Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice.
McLarty K; Moran MD; Scollard DA; Chan C; Sabha N; Mukherjee J; Guha A; McLaurin J; Nitz M; Houle S; Wilson AA; Reilly RM; Vasdev N
Nucl Med Biol; 2011 Oct; 38(7):953-9. PubMed ID: 21982567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]